Table S3.
Uncontrolled studies not included in pooled analysis
| Study grouping | Study | Dosea | Placebo control | Active control (doses) | Coadministration | Dosing protocol | Treatment duration | Reason for not including in pooled analysis |
|---|---|---|---|---|---|---|---|---|
| Open-label, safety | 02512 | 50, 100, 200 mg | None | None | Various antihypertensives (if BP uncontrolled with 200-mg dose) | Titration-to-effect | 14 months | Not a controlled study |
| 061 (Pfizer Inc. Data on file [JE3-01-02-061 –09 June 2005]) | 50, 100, 200 mg | None | None | Various antihypertensives (if BP uncontrolled with 200-mg dose) | Titration-to-effect | 12 months | Not a controlled study |
Note:
a
All regimens were QD.
Abbreviation: BP: blood pressure.